Skip to main content
. 2022 Jul;23(7):2263–2269. doi: 10.31557/APJCP.2022.23.7.2263

Table 3.

Living Status and Overall Survival of Locally Advanced Cervical Patients who had Failure after Primary Treatment According to Characteristic Features of the Patients and Type of Salvage Therapy

Characteristic features Status, n (%) OS
(month; 95% CI)
Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)
Alive Dead
Age 0.61 (0.29-1.25) 0.62 (0.26-1.46)
≤ 40 years (n=14) 5 (35.7) 9 (64.3) 17.1 (4.4-69.6)
> 40 years (n=71) 26 (36.6) 45 (63.4) 29.0 (4.8-67.9)
Stage 2.06 (1.19-3.56) 2.16 (1.16-4.02)
II (n=45) 23 (51.1) 22 (48.9) 31.5 (4.4-69.6)
III-IV (n=40) 8 (20.0) 32 (80.0) 25.3 (4.8-63.7)
Performance status 1.43 (0.90-2.27) 2.18 (1.15-4.12)
0-1 (n=80) 31 (38.8) 49 (61.2) 27.3 (4.4-69.6)
2-4 (n=5) - 5 (100) 27.3 (6.9-44.7)
Treatment-free interval 0.12 (0.06-0.24) 0.12 (0.06-0.24)
≤ 6 months (n=25) 2 (8.0) 23 (92.0) 14.1 (4.4-36.4)
> 6 months (n=41) 21 (51.2) 20 (48.8) 38.7 (9.5-69.6)
Type of failures 1.05 (0.73-1.52) 1.01 (0.64-1.59)
Local (n=45) 15 (33.3)  30 (64.7) 27.7 (20.6-34.9)
Systemic (n=26) 13 (50)  13 (50)  35.9 (32.6-50.4)
Local and Systemic (n=14) 3 (21.4) 11 (78.6)  16.8 (14.2.0-40.2)
Primary treatment 1.24 (0.72-2.13) 1.18 (0.61-2.26)
CCRT (n=39) 16 (41.0) 23 (59.0) 27.9 (4.8-64.4)
CCRT+ACT (n=46) 15 (32.6) 31 (77.4) 24.6 (4.4-69.6)
Salvage therapy 1.036 (0.87-1.23) 1.17 (0.84-1.63)
Radiation therapy (n=8) 2 (25.0) 6 (75) 31.7 (4.4-59.6)
Surgery (n=2) 2 (100) - 61.2 (52.7-69.6)
Chemotherapy (n=29) 9 (31.0) 20 (69.0) 25.2 (6.3-64)
Combine treatment (n=18) 10 (55.6) 8 (44.4) 37.0 (9.5-64.4)
Supportive care (n=9) - 9 (100) 7.9 (4.8-16.2)

Note: Performance status referred to performance status of the patients at the time of event; Treatment-free interval referred to duration from the last date of primary treatment to the date of event